Table of Contents Author Guidelines Submit a Manuscript
International Journal of Surgical Oncology
Volume 2011, Article ID 285840, 12 pages
http://dx.doi.org/10.1155/2011/285840
Review Article

Colorectal Liver Metastases

1Department of Surgery, Saint Agnes Hospital, Baltimore, MD 21229, USA
2Department of Surgery, Johns Hopkins University, Baltimore, MD 21231, USA
3Pancreatic and Hepatobiliary Surgery, Saint Agnes Hospital, 900 Caton Avenue, Mailbox no. 207, Baltimore, MD, 21229, USA

Received 6 December 2010; Accepted 22 March 2011

Academic Editor: S. Curley

Copyright © 2011 Ashraf J. Haddad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, J. Xu et al., “Cancer statistics,” CA Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Pestana, R. J. Reitemeier, C. G. Moertel, E. S. Judd, and M. B. Dockerty, “The natural history of carcinoma of the colon and rectum,” The American Journal of Surgery, vol. 108, no. 6, pp. 826–829, 1964. View at Google Scholar · View at Scopus
  3. S. Manfredi, C. Lepage, C. Hatem, O. Coatmeur, J. Faivre, and A. M. Bouvier, “Epidemiology and management of liver metastases from colorectal cancer,” Annals of Surgery, vol. 244, no. 2, pp. 254–259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Steele Jr. and T. S. Ravikumar, “Resection of hepatic metastases from colorectal cancer: biologic perspectives,” Annals of Surgery, vol. 210, no. 2, pp. 127–138, 1989. View at Google Scholar · View at Scopus
  5. M. A. Choti, “Controversies in the management of hepatic colorectal metastases,” Annals of Surgical Oncology, vol. 16, no. 9, pp. 2383–2384, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Adam, V. Delvart, G. Pascal et al., “Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival,” Annals of Surgery, vol. 240, no. 4, pp. 644–657, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. T. J. Gayowski, S. Iwatsuki, J. R. Madariaga et al., “Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors,” Surgery, vol. 116, no. 4, pp. 703–710, 1994. View at Google Scholar · View at Scopus
  8. J. Scheele, R. Stang, A. Altendorf-Hofmann, and M. Paul, “Resection of colorectal liver metastases,” World Journal of Surgery, vol. 19, no. 1, pp. 59–71, 1995. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Fong, J. Fortner, R. L. Sun, M. F. Brennan, and L. H. Blumgart, “Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases,” Annals of Surgery, vol. 230, no. 3, pp. 309–318, 1999. View at Publisher · View at Google Scholar
  10. M. A. Choti, J. V. Sitzmann, M. F. Tiburi et al., “Trends in long-term survival following liver resection for hepatic colorectal metastases,” Annals of Surgery, vol. 235, no. 6, pp. 759–766, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. E. K. Abdalla, J. N. Vauthey, L. M. Ellis et al., “Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases,” Annals of Surgery, vol. 239, no. 6, pp. 818–825, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. T. M. Pawlik, C. R. Scoggins, D. Zorzi et al., “Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases,” Annals of Surgery, vol. 241, no. 5, pp. 715–722, 2005. View at Publisher · View at Google Scholar
  13. A. C. Wei, P. D. Greig, D. Grant, B. Taylor, B. Langer, and S. Gallinger, “Survival after hepatic resection for colorectal metastases: a 10-year experience,” Annals of Surgical Oncology, vol. 13, no. 5, pp. 668–676, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. J. S. Tomlinson, W. R. Jarnagin, R. P. DeMatteo et al., “Actual 10-year survival after resection of colorectal liver metastases defines cure,” Journal of Clinical Oncology, vol. 25, no. 29, pp. 4575–4580, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. J. G. Fortner and Y. Fong, “Twenty-five-year follow-up for liver resection: the personal series of Dr. Joseph G. Fortner,” Annals of Surgery, vol. 250, no. 6, pp. 908–913, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Nordlinger, M. Guiguet, J.-C. Vaillant et al., “Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients,” Cancer, vol. 77, no. 7, pp. 1254–1262, 1996. View at Publisher · View at Google Scholar
  17. M. Schindl, S. J. Wigmore, E. J. Currie, F. Laengle, and O. J. Garden, “Prognostic scoring in colorectal cancer liver metastases: development and validation,” Archives of Surgery, vol. 140, no. 2, pp. 183–189, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Yasui, T. Hirai, T. Kato et al., “A new macroscopic classification predicts prognosis for patient with liver metastases from colorectal cancer,” Annals of Surgery, vol. 226, no. 5, pp. 582–586, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Iwatsuki, I. Dvorchik, J. R. Madariaga et al., “Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system,” Journal of the American College of Surgeons, vol. 189, no. 3, pp. 291–299, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. M. W. Kattan, M. Gonen, W. R. Jarnagin et al., “A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer,” Annals of Surgery, vol. 247, no. 2, pp. 282–287, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. M. R. Weiser, R. G. Landmann, M. W. Kattan et al., “Individualized prediction of colon cancer recurrence using a nomogram,” Journal of Clinical Oncology, vol. 26, no. 3, pp. 380–385, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. S. K. Reddy, M. W. Kattan, C. Yu et al., “Evaluation of peri-operative chemotherapy using a prognostic nomogram for survival after resection of colorectal liver metastases,” HPB, vol. 11, no. 7, pp. 592–599, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Nathan, M. C. de Jong, C. Pulitano et al., “Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients,” Journal of the American College of Surgeons, vol. 210, no. 5, pp. 755–764, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. S. K. Reddy, A. S. Barbas, and B. M. Clary, “Synchronous colorectal liver metastases: is it time to reconsider traditional paradigms of management?” Annals of Surgical Oncology, vol. 16, no. 9, pp. 2395–2410, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Benoist and B. Nordlinger, “The role of preoperative chemotherapy in patients with resectable colorectal liver metastases,” Annals of Surgical Oncology, vol. 16, no. 9, pp. 2385–2390, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Levi, A. Karaboue, L. Gorden et al., “Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability,” Cancer Chemotherapy and Pharmacology, vol. 67, no. 2, pp. 339–348, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Tanaka, R. Adam, H. Shimada, D. Azoulay, F. Levi, and H. Bismuth, “Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver,” British Journal of Surgery, vol. 90, no. 8, pp. 963–969, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. P. J. Allen, N. Kemeny, W. Jarnagin et al., “Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases,” Journal of Gastrointestinal Surgery, vol. 7, no. 1, pp. 109–115, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. D. G. Blazer III, Y. Kishi, D. M. Maru et al., “Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases,” Journal of Clinical Oncology, vol. 26, no. 33, pp. 5344–5351, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Adam, D. A. Wicherts, R. J. De Haas et al., “Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality?” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1635–1641, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. D. J. Gallagher, J. Zheng, M. Capanu et al., “Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases,” Annals of Surgical Oncology, vol. 16, no. 7, pp. 1844–1851, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Nordlinger, H. Sorbye, B. Glimelius et al., “Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial,” The Lancet, vol. 371, no. 9617, pp. 1007–1016, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. M. A. Choti, “Chemotherapy-associated hepatotoxicity: do we need to be concerned?” Annals of Surgical Oncology, vol. 16, no. 9, pp. 2391–2394, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. D. A. Kooby, Y. Fong, A. Suriawinata et al., “Impact of steatosis on perioperative outcome following hepatic resection,” Journal of Gastrointestinal Surgery, vol. 7, no. 8, pp. 1034–1044, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. J.-N. Vauthey, T. M. Pawlik, D. Ribero et al., “Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases,” Journal of Clinical Oncology, vol. 24, no. 13, pp. 2065–2072, 2006. View at Publisher · View at Google Scholar
  36. T. M. Pawlik, K. Olino, A. L. Gleisner, M. Torbenson, R. Schulick, and M. A. Choti, “Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome,” Journal of Gastrointestinal Surgery, vol. 11, no. 7, pp. 860–868, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Normanno, S. Tejpar, F. Morgillo, A. De Luca, E. Van Cutsem, and F. Ciardiello, “Implications for KRAS status and EGFR-targeted therapies in metastatic CRC,” Diseases of the Colon and Rectum, vol. 6, no. 9, pp. 519–527, 2009. View at Publisher · View at Google Scholar
  39. F. Kabbinavar, H. I. Hurwitz, L. Fehrenbacher et al., “Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer,” Journal of the American Society of Clinical Oncology, vol. 21, no. 1, pp. 60–65, 2003. View at Google Scholar · View at Scopus
  40. D. Zorzi, Y. S. Chun, D. C. Madoff, E. K. Abdalla, and J. N. Vauthey, “Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases,” Annals of Surgical Oncology, vol. 15, no. 10, pp. 2765–2772, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. B. Gruenberger, D. Tamandl, J. Schueller et al., “Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 11, pp. 1830–1835, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. P. Pessaux, M. P. Chenard, P. Bachellier, and D. Jaeck, “Consequences of chemotherapy on resection of colorectal liver metastases,” Journal of Visceral Surgery, vol. 147, no. 4, pp. e193–e201, 2010. View at Google Scholar
  43. B. Aussilhou, S. Dokmak, S. Faivre, V. Paradis, V. Vilgrain, and J. Belghiti, “Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab,” Annals of Surgical Oncology, vol. 16, no. 6, pp. 1553–1559, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Klinger, S. Eipeldauer, S. Hacker et al., “Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectalcancer liver metastases,” European Journal of Surgical Oncology, vol. 35, no. 5, pp. 515–520, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Ribero, H. Wang, M. Donadon et al., “Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases,” Cancer, vol. 110, no. 12, pp. 2761–2767, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Iguchi, R. Kobayashi, M. Yoshida et al., “Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation,” Bone Marrow Transplantation, vol. 27, no. 11, pp. 1173–1180, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Vogt, R. Raab, B. Ringe, and R. Pichlmayr, “Resection of synchronous liver metastases from colorectal cancer,” World Journal of Surgery, vol. 15, no. 1, pp. 62–67, 1991. View at Google Scholar · View at Scopus
  48. D. Jaeck, P. Bachellier, J. C. Weber et al., “Surgical strategy in the treatment of synchronous hepatic metastases of colorectal cancers. Analysis of a series of 59 operated on patients,” Chirurgie, vol. 124, no. 3, pp. 258–263, 1999. View at Publisher · View at Google Scholar
  49. R. Martin, P. B. Paty, Y. Fong et al., “Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis,” Journal of the American College of Surgeons, vol. 197, no. 2, pp. 233–241, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. J. C. Weber, P. Bachellier, E. Oussoultzoglou, and D. Jaeck, “Simultaneous resection of colorectal primary tumour and synchronous liver metastases,” British Journal of Surgery, vol. 90, no. 8, pp. 956–962, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. K. Tanaka, H. Shimada, K. Matsuo et al., “Outcome after simultaneous colorectal and hepatic resection for colorectal cancer with synchronous metastases,” Surgery, vol. 136, no. 3, pp. 650–659, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. H. K. Chua, K. Sondenaa, G. G. Tsiotos, D. R. Larson, B. G. Wolff, and D. M. Nagorney, “Concurrent vs. staged colectomy and hepatectomy for primary colorectal cancer with synchronous hepatic metastases,” Diseases of the Colon and Rectum, vol. 47, no. 8, pp. 1310–1316, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Thelen, S. Jonas, C. Benckert et al., “Simultaneous versus staged liver resection of synchronous liver metastases from colorectal cancer,” International Journal of Colorectal Disease, vol. 22, no. 10, pp. 1269–1276, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. O. Turrini, F. Viret, J. Guiramand, B. Lelong, T. Bège, and J. R. Delpero, “Strategies for the treatment of synchronous liver metastasis,” European Journal of Surgical Oncology, vol. 33, no. 6, pp. 735–740, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. T. D. Yan, F. Chu, D. Black, D. W. King, and D. L. Morris, “Synchronous resection of colorectal primary cancer and liver metastases,” World Journal of Surgery, vol. 31, no. 7, pp. 1496–1501, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Capussotti, L. Vigano, A. Ferrero, R. Lo Tesoriere, D. Ribero, and R. Polastri, “Timing of resection of liver metastases synchronous to colorectal tumor: proposal of prognosis-based decisional model,” Annals of Surgical Oncology, vol. 14, no. 3, pp. 1143–1150, 2007. View at Google Scholar · View at Scopus
  57. I. Vassiliou, N. Arkadopoulos, T. Theodosopoulos et al., “Surgical approaches of resectable synchronous colorectal liver metastases: timing considerations,” World Journal of Gastroenterology, vol. 13, no. 9, pp. 1431–1434, 2007. View at Google Scholar · View at Scopus
  58. S. K. Reddy, T. M. Pawlik, D. Zorzi et al., “Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis,” Annals of Surgical Oncology, vol. 14, no. 12, pp. 3481–3491, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Slupski, Z. Wlodarczyk, M. Jasinski, M. Masztalerz, and J. Tujakowski, “Outcomes of simultaneous and delayed resections of synchronous colorectal liver metastases,” Canadian Journal of Surgery, vol. 52, no. 6, pp. E241–E244, 2009. View at Google Scholar · View at Scopus
  60. R. C. Martin II, V. Augenstein, N. P. Reuter, C. R. Scoggins, and K. M. McMasters, “Simultaneous versus staged resection for synchronous colorectal cancer liver metastases,” Journal of the American College of Surgeons, vol. 208, no. 5, pp. 842–850, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. J. G. Hillingso and P. Wille-jorgensen, “Staged or simultaneous resection of synchronous liver metastases from colorectal cancer—a systematic review,” Colorectal Disease, vol. 11, no. 1, pp. 3–10, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Chen, Q. Li, C. Wang, H. Zhu, Y. Shi, and G. Zhao, “Simultaneous vs. staged resection for synchronous colorectal liver metastases: a metaanalysis,” International Journal of Colorectal Disease, vol. 26, no. 2, pp. 191–199, 2011. View at Publisher · View at Google Scholar
  63. J. S. Gold, C. Are, P. Kornprat et al., “Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients,” Annals of Surgery, vol. 247, no. 1, pp. 109–117, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Scheele, R. Stangl, and A. Altendorf-Hofmann, “Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history,” British Journal of Surgery, vol. 77, no. 11, pp. 1241–1246, 1990. View at Publisher · View at Google Scholar · View at Scopus
  65. S. C. Cunningham, M. A. Choti, and T. M. Pawlik, “Two-stage hepatectomy for colorectal cancer hepatic metastases,” Current Colorectal Cancer Reports, vol. 4, pp. 93–99, 2008. View at Google Scholar
  66. S. Togo, Y. Nagano, H. Masui et al., “Two-stage hepatectomy for multiple bilobular liver metastases from colorectal cancer,” Hepatogastroenterology, vol. 52, no. 63, pp. 913–919, 2005. View at Google Scholar · View at Scopus
  67. D. Elias, T. De Baere, A. Roche, M. Ducreux, J. Leclere, and P. Lasser, “During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma,” British Journal of Surgery, vol. 86, no. 6, pp. 784–788, 1999. View at Publisher · View at Google Scholar · View at Scopus
  68. N. Selzner, B. C. Pestalozzi, Z. Kadry, M. Selzner, S. Wildermuth, and P. A. Clavien, “Downstaging colorectal liver metastases by concomitant unilateral portal vein ligation and selective intra-arterial chemotherapy,” British Journal of Surgery, vol. 93, no. 5, pp. 587–592, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. S. Tsai, H. P. Marques, M. C. De Jong et al., “Two-stage strategy for patients with extensive bilateral colorectal liver metastases,” HPB, vol. 12, no. 4, pp. 262–269, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. M. C. De Jong, C. Pulitano, D. Ribero et al., “Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients,” Annals of Surgery, vol. 250, no. 3, pp. 440–448, 2009. View at Publisher · View at Google Scholar
  71. M. C. de Jong, C. Pulitano, D. Ribero et al., “Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients,” Annals of Surgery, vol. 250, no. 3, pp. 440–447, 2009. View at Publisher · View at Google Scholar
  72. M. C. de Jong, S. C. Mayo, C. Pulitano et al., “Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis,” Journal of Gastrointestinal Surgery, vol. 13, no. 12, pp. 2141–2151, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. H. J. Wanebo, B. J. Kennedy, D. P. Winchester, A. Fremgen, and A. K. Stewart, “Gastric carcinoma: does lymph node dissection alter survival?” Journal of the American College of Surgeons, vol. 183, no. 6, pp. 616–624, 1996. View at Google Scholar
  74. E. Vibert, F. Bretagnol, A. Alves, M. Pocard, P. Valleur, and Y. Panis, “Multivariate analysis of predictive factors for early postoperative death after colorectal surgery in patients with colorectal cancer and synchronous unresectable liver metastases,” Diseases of the Colon and Rectum, vol. 50, no. 11, pp. 1776–1782, 2007. View at Publisher · View at Google Scholar
  75. G. Galizia, E. Lieto, M. Orditura et al., “First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases,” Archives of Surgery, vol. 143, no. 4, pp. 352–358, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. M. M. Kemeny, “Surgery should be the primary treatment of synchronous colorectal metastases in the asymptomatic patient,” Annals of Surgical Oncology, vol. 13, no. 2, pp. 140–141, 2006. View at Google Scholar
  77. N. J. Petrelli, “Expressing the prochemotherapy position on treatment of synchronous colorectal metastases in the asymptomatic patient,” Annals of Surgical Oncology, vol. 13, no. 2, pp. 137–139, 2006. View at Publisher · View at Google Scholar
  78. A. D. Cook, R. Single, and L. E. McCahill, “Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000,” Annals of Surgical Oncology, vol. 12, no. 8, pp. 637–645, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. L. K. Temple, L. Hsieh, W. D. Wong, L. Saltz, and D. Schrag, “Use of surgery among elderly patients with stage IV colorectal cancer,” Journal of Clinical Oncology, vol. 22, no. 17, pp. 3475–3484, 2004. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Benoist, K. Pautrat, E. Mitry, P. Rougier, C. Penna, and B. Nordlinger, “Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases,” British Journal of Surgery, vol. 92, no. 9, pp. 1155–1160, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. L. Ruo, C. Gougoutas, P. B. Paty, J. G. Guillem, A. M. Cohen, and W. D. Wong, “Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients,” Journal of the American College of Surgeons, vol. 196, no. 5, pp. 722–728, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. G. A. Poultsides, E. L. Servais, L. B. Saltz et al., “Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment,” Journal of Clinical Oncology, vol. 27, no. 20, pp. 3379–3384, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Nuzzo, F. Giuliante, F. Ardito et al., “Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy,” Journal of Gastrointestinal Surgery, vol. 11, no. 3, pp. 318–324, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. C. Breedis and G. Young, “The blood supply of neoplasms in the liver,” The American journal of pathology, vol. 30, no. 5, pp. 969–977, 1954. View at Google Scholar
  85. N. B. Ackerman, “The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth,” Surgery, vol. 75, no. 4, pp. 589–596, 1974. View at Google Scholar · View at Scopus
  86. D. J. Martinelli, S. Wadler, C. W. Bakal et al., “Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma,” Cancer, vol. 74, no. 6, pp. 1706–1712, 1994. View at Publisher · View at Google Scholar
  87. H. S. Salman, J. Cynamon, M. Jagust et al., “Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver,” Clinical Colorectal Cancer, vol. 2, no. 3, pp. 173–179, 2002. View at Google Scholar · View at Scopus
  88. M. Albert, M. V. Kiefer, W. Sun et al., “Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol,” Cancer, vol. 117, no. 2, pp. 343–352, 2011. View at Publisher · View at Google Scholar
  89. T. P. Pwint, R. Midgley, and D. J. Kerr, “Regional hepatic chemotherapies in the treatment of colorectal cancer metastases to the liver,” Seminars in Oncology, vol. 37, no. 2, pp. 149–159, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. Meta-Analysis Group In Cancer, “Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer,” Journal of the National Cancer Institute, vol. 88, no. 5, pp. 252–258, 1996. View at Publisher · View at Google Scholar
  91. N. Kemeny, W. Jarnagin, P. Paty et al., “Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer,” Journal of Clinical Oncology, vol. 23, no. 22, pp. 4888–4896, 2005. View at Publisher · View at Google Scholar · View at Scopus
  92. R. K. Ausman, “Development of a technic for isolated perfusion of the liver,” New York state journal of medicine, vol. 61, pp. 3993–3997, 1961. View at Google Scholar · View at Scopus
  93. H. R. Alexander Jr. and C. C. Butler, “Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases,” Cancer Journal, vol. 16, no. 2, pp. 132–141, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. H. R. Alexander, D. L. Bartlett, S. K. Libutti et al., “Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center,” Annals of Surgical Oncology, vol. 16, no. 7, pp. 1852–1859, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. L. B. van Iersel, M. Koopman, C. J. van de Velde et al., “Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy,” Annals of Oncology, vol. 21, no. 8, pp. 1662–1667, 2010. View at Publisher · View at Google Scholar
  96. R. A. Sharma, G. A. Van Hazel, B. Morgan et al., “Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy,” Journal of Clinical Oncology, vol. 25, no. 9, pp. 1099–1106, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Townsend, T. Price, and C. Karapetis, “Selective internal radiation therapy for liver metastases from colorectal cancer,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD007045, 2009. View at Google Scholar · View at Scopus
  98. G. Van Hazel, A. Blackwell, J. Anderson et al., “Randomised phase 2 trial of SIR-spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer,” Journal of Surgical Oncology, vol. 88, no. 2, pp. 78–85, 2004. View at Publisher · View at Google Scholar · View at Scopus
  99. S. C. Cunningham, M. A. Choti, E. C. Bellavance, and T. M. Pawlik, “Palliation of hepatic tumors,” Surgical Oncology, vol. 16, no. 4, pp. 277–291, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. D. R. Carpizo, C. Are, W. Jarnagin et al., “Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center,” Annals of Surgical Oncology, vol. 16, no. 8, pp. 2138–2146, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. J. Pfannschmidt, H. Hoffmann, and H. Dienemann, “Reported outcome factors for pulmonary resection in metastatic colorectal cancer,” Journal of Thoracic Oncology, vol. 5, supplement 2, no. 6, pp. S172–S178, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. D. R. Carpizo and M. D'Angelica, “Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease,” Annals of Surgical Oncology, vol. 16, no. 9, pp. 2411–2421, 2009. View at Publisher · View at Google Scholar · View at Scopus